<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275833</url>
  </required_header>
  <id_info>
    <org_study_id>RESTORE AV</org_study_id>
    <nct_id>NCT01275833</nct_id>
  </id_info>
  <brief_title>Restoration of Atrioventricular Synchrony Trial</brief_title>
  <acronym>RESTORE-AV</acronym>
  <official_title>Restoration of Atrioventricular Synchrony Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to observe the effects of restoring atrioventricular (AV)
      synchrony in subjects with prolonged PR intervals. This will be assessed both acutely and
      chronically using echocardiographic and functional measurements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult subject recruitment
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Range finding of functional and hemodynamic changes using echocardiographic determined measures.</measure>
    <time_frame>6 months</time_frame>
    <description>Echocardiographic measures will include, but not be limited to, left ventricular volumes, left ventricular diameters, and ejection fraction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>First Degree AV Block</condition>
  <arm_group>
    <arm_group_label>Device programming that modifies AV timing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Device programming that allows intrinsic AV timing.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy-defibrillator</intervention_name>
    <description>Device programming that modifies AV timing</description>
    <arm_group_label>Device programming that modifies AV timing</arm_group_label>
    <other_name>First degree AV block</other_name>
    <other_name>Long PR interval</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet current indications for an implantable cardioverter-defibrillator (ICD) implant
             with:

          -  QRS width &lt; 120 msec

          -  Left ventricular ejection fraction (LVEF) &lt; 35% (no more than 180 days prior to
             enrollment)

          -  NYHA functional class II/III

          -  Optimal pharmacological heart failure therapy

          -  PR interval &gt;/= 230 msec

          -  Ability to tolerate protocol required programming

          -  Access to a telephone line compatible with the LATITUDEÂ® Communicator

          -  Subjects in sinus rhythm at the time of the baseline visit and who are expected to
             remain in sinus rhythm for the duration of the study

          -  Age 18 or above, or of legal age to give informed consent specific to state and
             national law

          -  Willing and capable of providing informed consent, undergoing a device implant,
             participating in all testing associated with this clinical investigation at an
             approved clinical investigational center and return to the investigational center at
             the intervals defined by this protocol

        Exclusion Criteria:

          -  Previously placed pacemaker, ICD, or CRT device

          -  Inability or refusal to sign the Informed Consent Form

          -  Documented life expectancy of less than 12 months or expected to undergo heart
             transplant within the next 12 months

          -  Have tricuspid valve disease or who are likely to receive a mechanical tricuspid
             valve during the course of the clinical investigation

          -  Inability or refusal to comply with the follow-up schedule

          -  Have a neuromuscular, orthopedic, or other noncardiac condition that prevents subject
             from normal unsupported walking for the six minute hall walk test

          -  Have surgically uncorrected primary valvular heart disease

          -  Second or third degree atrioventricular block (AVB)

          -  Permanent or persistent atrial tachyarrhythmia that is refractory to all therapies

          -  Have had cardiac surgery, percutaneous coronary intervention, or myocardial
             infarction within 3 months of signing consent or who are likely to undergo a cardiac
             surgery or procedure in the foreseeable future

          -  Enrolled in any concurrent study unless written approval has been obtained from
             Boston Scientific or The Integra Group

          -  Women who are pregnant or plan to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Olshansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Day, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 3, 2012</lastchanged_date>
  <firstreceived_date>January 2, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable cardioverter-defibrillator (ICD) indicated patients</keyword>
  <keyword>First Degree AV block.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
